Acción PROGEN PROSTATYPE GENOMICS AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Prostatype Genomics AB

Acciones

PROGEN

SE0014684569

Mercado cerrado - Nasdaq Stockholm
Otros sitios de cotización
 17:29:55 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,0328 SEK -10,87 % Gráfico intradía de Prostatype Genomics AB -13,23 % -65,47 %
18/04 Prostatype Genomics anuncia resultados provisionales muy sólidos del estudio de seguimiento a largo plazo con Prostatype en Uppsala CI
17/04 Prostatype Genomics actualiza los avances significativos del estudio estadounidense con Prostatype®. CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Prostatype Genomics publishes Annual Report for 2023
NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)
Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3)
Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala
Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala
Prostatype Genomics updates on significant progress in the US study with Prostatype®
Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®
Prostatype Genomics Wraps Up Prostate Cancer Genetic Test Study with Positive Results
Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain
Prostatype Genomics Announces Strong Positive Final Results from Multicentre Study with Prostatype®? in Spain
Prostatype Genomics AB Announces Strong Positive Final Results from Multicentre Study with Prostatype in Spain
The exercise period for Prostatype Genomic's warrants of series 3 begins today
Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States
Prostatype Genomics Enters into Collaboration with Professor E. David Crawford University of California San Diego, in Preparation for the Commercial Launch of Prostatype in the United States
Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala
Prostatype Genomics' long-term study with Uppsala University Hospital will be presented at the AUA conference in the US in May 2024
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023
Prostatype Genomics publishes year-end report for 2023
Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market
Prostatype Genomics acquires CLIA Certificate to facilitate rapid US market launch with a significantly stronger financial outlook
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción PROGEN
  4. Noticias Prostatype Genomics AB
  5. Otros idiomas